A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement

被引:13
|
作者
Heidenreich, Paul A. [1 ]
Tsai, Vivian [2 ]
Curtis, Jeptha [4 ]
Wang, Yongfei [4 ]
Turakhia, Mintu P. [1 ]
Masoudi, Frederick A. [3 ]
Varosy, Paul D. [3 ]
Goldstein, Mary K. [1 ]
机构
[1] VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA
[2] Palo Alto Med Fdn, Palo Alto, CA USA
[3] Univ Colorado Anschutz Med Campus, Dept Med, Aurora, CO USA
[4] Yale Univ, Sch Med, New Haven, CT USA
关键词
REGRESSION TREE ANALYSIS; HEART-FAILURE; SURVIVAL; STRATIFICATION; CLASSIFICATION; PREDICTION; REGISTRY; THERAPY; BENEFIT; DEATH;
D O I
10.1016/j.ahj.2014.12.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective We sought to determine survival for patients with heart failure after an implantation of an implantable cardioverter defibrillator (ICD) for primary prevention in the United States and to develop a simple model that would predict mortality risk. Background Clinical trials have found that patients with heart failure with a 1-year mortality risk near 20% may not benefit from an ICD. Methods We identified patients from the ICD Registry of the National Cardiovascular Disease Registries who underwent ICD implantation for primary prevention from 2007 to 2009. Two risk scores for mortality were developed in 2 cohorts: one limited to those with a B-type natriuretic peptide (BNP) value and a second for all patients. The scores were obtained from derivation datasets and tested in a validation sets using logistic regression models and classification and regression trees. Results In a primary prevention population with BNP available (18,725) the 6 variables most predictive of 1-year mortality were age >= 75, BNP >= 700 pg/mL, chronic lung disease, dialysis, blood urea nitrogen >= 30 mg/dL, and systolic blood pressure <120 mmHg. Patients with zero risk factors had a 3.3% one-year mortality compared to a 66.7% one-year mortality for those with all 6 risk factors. Those with >= 3 risk factors (24.0% of the population) had a 25.8% one-year mortality. A second score using a larger cohort that did not consider BNP identified similar risk factors. Conclusions A simple validated risk score can identify patients at high and low risk for death within a year after ICD placement. A large fraction of those currently implanted with an ICD in the United States have a high 1-year mortality and may not benefit from ICD therapy.
引用
收藏
页码:281 / U119
页数:11
相关论文
共 50 条
  • [21] Update on primary prevention implantable cardioverter-defibrillator therapy
    Epstein A.E.
    Current Cardiology Reports, 2009, 11 (5) : 335 - 342
  • [22] Clinical markers of organ dysfunction associated with increased 1-year mortality post-implantable cardioverter defibrillator implantation
    Chong, Daniel
    Tan, Boon Yew
    Ho, Kah Leng
    Liew, Reginald
    Teo, Wee Siong
    Ching, Chi Keong
    EUROPACE, 2013, 15 (04): : 508 - 514
  • [23] THE ECONOMIC IMPACT OF THE USE OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN PRIMARY PREVENTION
    Madotto, F.
    Conti, S.
    Chiodini, V
    Mantovani, L. G.
    Achilli, F.
    Curnis, A.
    Landolina, M.
    Lunati, M.
    Marzegalli, M.
    Proclemer, A.
    Fornari, C.
    Cesana, G.
    VALUE IN HEALTH, 2015, 18 (07) : A337 - A337
  • [24] Risk factors for mortality within one-year after implantable cardioverter defibrillator implantation: a nationwide study
    Alhakak, A.
    Ostergaard, L.
    Butt, J. H.
    Vinther, M.
    Philbert, B. T.
    Jacobsen, P. K.
    Yafasova, A.
    Torp-Pedersen, C.
    Kober, L.
    Fosbol, E.
    Mogensen, U. M.
    Weeke, P. E.
    EUROPEAN HEART JOURNAL, 2020, 41 : 790 - 790
  • [25] Incidence of Implantable Cardioverter Defibrillator Therapy and Mortality in Primary and Secondary Prevention of Sudden Cardiac Death
    Konstantino, Yuval
    Shafat, Tali
    Novack, Victor
    Novack, Lena
    Amit, Guy
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2015, 17 (12): : 760 - 763
  • [26] MADIT II trial: A 2002 breakthrough in primary prevention of mortality with implantable cardioverter-defibrillator
    Zareba, Wojciech
    HEART RHYTHM, 2025, 22 (04) : 882 - 883
  • [27] Mortality risk score in primary prevention implantable cardioverter defibrillator recipients with non-ischaemic or ischaemic heart disease
    Borleffs, C. Jan Willem
    van Welsenes, Guido H.
    van Bommel, Rutger J.
    van der Velde, Enno T.
    Bax, Jeroen J.
    van Erven, Lieselot
    Putter, Hein
    van der Bom, Johanna G.
    Rosendaal, Frits R.
    Schalij, Martin J.
    EUROPEAN HEART JOURNAL, 2010, 31 (06) : 712 - 718
  • [28] Clinical Impact of Implantable Cardioverter-Defibrillator Therapy and Mortality Prediction Model for Effective Primary Prevention in Korean Patients
    Bae, Myung Hwan
    Cho, Yongkeun
    Hwang, Jongmin
    Park, Hyoung-Seob
    Han, Seongwook
    Lee, Young Soo
    Cho, Hyun Jun
    Jung, Byung Chun
    Lee, Chan-Hee
    Hyun, Dae-Woo
    Park, Jong Sung
    Ahn, Jinhee
    Kim, Ki-Hun
    Shin, Dong-Gu
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (09)
  • [29] The Effect of Renal Function on Survival After Implantable Cardioverter Defibrillator Placement
    Hager, Casey S.
    Blackwell, Jeffrey
    Jain, Sunil
    Culp, Benjamin
    Davis, Elaine
    Hanlon, Charin
    Chiles, Christopher D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A134 - A134
  • [30] Effect of technological advances on survival after implantable cardioverter defibrillator placement
    Herre, JM
    Tenzer, MM
    Klevan, LR
    McGuire, B
    Baker, L
    Szentpetery, S
    Rich, JB
    Bernstein, RC
    CIRCULATION, 1996, 94 (08) : 575 - 575